Search

Your search keyword '"DARICELLO, G"' showing total 3 results
Start Over Author "DARICELLO, G" Topic prostate cancer
3 results on '"DARICELLO, G"'

2. Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study.

Author

Serretta, V., Daricello, G., Dispensa, N., Allegro, R., Pavone, C., and Pavone-Macaluso, M.

Subjects
*PROSTATE cancer treatment, *CANCER treatment, *METASTASIS, *ANTIANDROGENS
Abstract

OBJECTIVE To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2–4N0–3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an objective response in 17 (41%) patients; 20 (49%) had stable disease while four (10%) progressed. There were objective responses, lasting up to 150 months, in 82% of those with M0 and in 18% with M1 disease (P = 0.05). The median time to progression in patients with an objective response and stable disease was 45 and 16 months, respectively (P < 0.001). Thirty-one patients (76%) died from prostate cancer and 10 (24%) from unrelated diseases. The median survival was 67 and 36 months in patients with an objective response and stable disease, respectively (P < 0.001). There was an improvement in performance status in 85% and reduction in bone pain in 83% of the patients; sexual activity was maintained in 63%. CONCLUSION Monotherapy with flutamide is well tolerated. Objective responses are more frequent in patients with locally advanced disease. Patients with an objective response within 6 months have a prolonged progression-free and overall survival. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

3. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

Author

Vincenzo Serretta, Darvinio Melloni, Anna Martorana, A Catanese, R. Liotta, F Aragona, G. Daricello, Rosalinda Allegro, SERRETTA, V, CATANESE, A, DARICELLO, G, LIOTTA, R, ALLEGRO, R, MARTORANA, A, and MELLONI, D

Subjects
Male, Risk, Cancer Research, medicine.medical_specialty, Time Factors, Prostate biopsy, medicine.drug_class, Urology, Antibiotics, Prostatitis, Unnecessary Procedures, urologic and male genital diseases, Settore MED/24 - Urologia, Diagnosis, Differential, Prostate cancer, Ciprofloxacin, Biopsy, Carcinoma, Humans, Medicine, Ultrasonography, Interventional, Aged, Aged, 80 and over, Palpation, medicine.diagnostic_test, business.industry, Patient Selection, Biopsy, Needle, Prostate, Prostatic Neoplasms, Cancer, Histology, Organ Size, Middle Aged, Prostate-Specific Antigen, medicine.disease, Anti-Bacterial Agents, Oncology, business, prostate-specific antigen (PSA), prostatitis, prostate carcinoma, Follow-Up Studies
Abstract

Microscopic foci of prostatitis may induce prostate-specific antigen (PSA) increase. PSA reduction after antibiotics might identify those patients in whom biopsy can be avoided. Ninety-nine patients received ciprofloxacin for 3 weeks, of whom 59 showed PSA reduction. Histology detected small foci of prostatitis in 65% of cases. Carcinoma was found in 40 and 20.3% of patients with unchanged or decreased PSA, respectively (P=0.03). No cancer was detected if PSA decreased below 4 ng/ml or more than 70%. Biopsy can be postponed, with a low risk of missing a cancer, if PSA decreases more than 70% or below 4 ng/ml.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results